Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
On Sept. 16 Novo Nordisk (NYSE: NVO) and Korro Bio (NASDAQ: KRRO) announced that they'd be starting a new drug-development ...
Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...
It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...
Based on the results of the trial, drugmaker Novo Nordisk has asked U.S. regulators to expand use of the medication for kids ...
Jared Holz, Mizuho, joins 'Fast Money' to talk how possible Medicare price negotiations are impacting Novo Nordisk shares.
As Novo Nordisk rakes in billions, Sen. Bernie Sanders and public health advocates demand answers on why U.S. patients are charged sky-high prices for life-saving drugs like Ozempic while generics ...
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...
Novo Nordisk Inc. was sued Friday by five former employees who say the pharmaceutical company mismanages its $2.3 billion ...
NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines for cardiometabolic and rare diseases, utilizing NanoVation's lipid nanoparticle technology. The deal includes research ...
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback